IRIS
CORTI, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.938
EU - Europa 5.506
NA - Nord America 5.220
SA - Sud America 1.571
Continente sconosciuto - Info sul continente non disponibili 146
AF - Africa 130
OC - Oceania 5
Totale 18.516
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.935
RU - Federazione Russa 3.021
SG - Singapore 2.175
CN - Cina 1.923
BR - Brasile 1.290
HK - Hong Kong 747
SE - Svezia 688
IT - Italia 686
VN - Vietnam 522
RO - Romania 279
FR - Francia 271
DE - Germania 185
BD - Bangladesh 171
CA - Canada 126
AR - Argentina 108
GB - Regno Unito 106
IN - India 94
FI - Finlandia 78
EC - Ecuador 61
MX - Messico 56
ID - Indonesia 53
IE - Irlanda 44
ZA - Sudafrica 43
AT - Austria 39
JP - Giappone 38
IQ - Iraq 33
CO - Colombia 31
PY - Paraguay 29
NL - Olanda 25
PL - Polonia 24
TR - Turchia 24
JM - Giamaica 23
MA - Marocco 18
ES - Italia 17
CR - Costa Rica 16
EG - Egitto 16
PK - Pakistan 16
UZ - Uzbekistan 15
VE - Venezuela 15
MY - Malesia 14
SA - Arabia Saudita 14
PE - Perù 13
CL - Cile 12
UA - Ucraina 12
AE - Emirati Arabi Uniti 10
KE - Kenya 10
PH - Filippine 10
UY - Uruguay 10
LT - Lituania 9
NP - Nepal 9
TN - Tunisia 9
TT - Trinidad e Tobago 9
AZ - Azerbaigian 8
HN - Honduras 8
IR - Iran 8
NI - Nicaragua 8
DO - Repubblica Dominicana 7
GT - Guatemala 7
AL - Albania 6
GP - Guadalupe 6
NG - Nigeria 6
DZ - Algeria 5
GE - Georgia 5
IL - Israele 5
JO - Giordania 5
KR - Corea 5
KZ - Kazakistan 5
SN - Senegal 5
SV - El Salvador 5
AU - Australia 4
ET - Etiopia 4
PA - Panama 4
TH - Thailandia 4
BB - Barbados 3
BE - Belgio 3
BH - Bahrain 3
CI - Costa d'Avorio 3
GA - Gabon 3
HR - Croazia 3
KW - Kuwait 3
LB - Libano 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
BM - Bermuda 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CW - ???statistics.table.value.countryCode.CW??? 2
CY - Cipro 2
DM - Dominica 2
LV - Lettonia 2
OM - Oman 2
PS - Palestinian Territory 2
AM - Armenia 1
AO - Angola 1
BW - Botswana 1
CD - Congo 1
CG - Congo 1
CH - Svizzera 1
GD - Grenada 1
Totale 18.359
Salva come PNG Salva come JPEG
Città #
Singapore 874
Ashburn 738
Hong Kong 738
Moscow 670
San Jose 635
Dallas 530
Shanghai 305
Council Bluffs 290
Hefei 287
Princeton 267
Lawrence 266
Milan 238
Lauterbourg 236
Ho Chi Minh City 185
Beijing 144
New York 125
São Paulo 119
Santa Clara 106
Hanoi 102
Los Angeles 87
Phoenix 83
Helsinki 59
Miano 53
The Dalles 51
Rio de Janeiro 46
North Bergen 44
Dublin 42
Nuremberg 41
Pune 34
Rome 34
Da Nang 30
Tokyo 29
Chicago 28
Guangzhou 28
Montreal 27
Orem 26
Toronto 25
Atlanta 24
Boardman 24
Brooklyn 24
Frankfurt am Main 24
Quito 24
Hangzhou 23
Denver 22
Haiphong 22
London 22
Curitiba 21
Brasília 20
Warsaw 20
Columbus 19
Johannesburg 19
Munich 19
Buffalo 18
Campinas 18
Chennai 18
Dhaka 18
Mexico City 18
Vienna 17
Washington 17
Guarulhos 16
Hải Dương 16
Kingston 16
San Francisco 16
Seattle 16
Stockholm 16
Belo Horizonte 15
Houston 15
Naples 15
Philadelphia 15
Guayaquil 14
Salvador 14
Goiânia 13
Manchester 13
Poplar 13
Shenzhen 13
Turku 13
Asunción 12
Baghdad 12
Cleveland 12
Jakarta 12
Manaus 12
Porto Alegre 12
San José 12
Santo André 12
Tashkent 12
Thái Bình 12
Boston 11
Charlotte 11
Fortaleza 11
Turin 11
Xi'an 11
Biên Hòa 10
Cape Town 10
Miami 10
Pittsburgh 10
Alexandria 9
Las Vegas 9
Lima 9
Montevideo 9
Recife 9
Totale 8.582
Salva come PNG Salva come JPEG
Nome #
A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer 402
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth 232
Chromogranin A regulates vesicle storage and mitochondrial dynamics to influence insulin secretion 199
[Activation and role of the tumor necrosis factor-alpha in congestive heart failure]. FT Attivazione e ruolo del fattore di necrosi tumorale alfa nello scompenso cardiaco congestizio. 154
Hematopoietic stem-and progenitor-cell gene therapy for hurler syndrome 149
Gold nanorod–assisted theranostic solution for nonvisible residual disease in bladder cancer 144
Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome 141
A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins 134
An innovative platform approach for the development of ex-vivo gene therapies for the treatment of lysosomal storage diseases with skeletal involvement 132
Early diagnosis of bladder cancer by photoacoustic imaging of tumor-targeted gold nanorods 127
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: Final results of a phase 2 trial 127
A pilot phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma 123
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 122
Chromogranin A plasma levels predict mortality in COVID-19 118
Altered Chromogranin A Circulating Levels in Meniere’s Disease 117
Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α 116
A simple and robust nanosystem for photoacoustic imaging of bladder cancer based on α5β1-targeted gold nanorods 115
Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging 115
CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study 111
Aminopeptidase N (CD13)-positive bone marrow-derived cells induce angiogenesis and tumor growth: A potential non-malignant immune cell target against cancer 108
Contrast enhanced photoacoustic detection of fibrillar collagen in the near infrared region-I 103
Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models 101
A receptor-antibody sandwich assay for teicoplanin. 100
Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis 97
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma 97
Production and characterisation of human recombinant single chain urokinase-type plasminogen activator from mouse cells 96
Chromogranin-A production and fragmentation in patients with Takayasu arteritis. 96
A stapled chromogranin A-derived peptide is a potent dual ligand for integrins αvβ6 and αvβ8 95
Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma 95
A rapid method for monitoring DNA labelling reactions with haptens. 94
A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator. 94
Affinity enhancement of complementary peptide recognition 94
A novel aminopeptidase N/CD13 inhibitor selectively targets an endothelial form of CD13 after coupling to proteins 94
A new method for rapid and simple pregnancy detection using gold-labelled antibodies 93
Tumor targeting with biotinylated tumor necrosis factor alpha: Structure-activity relationships and mechanism of action on avidin pretargeted tumor cells 88
Quantification of Chromogranin A and Its Fragments in Biological Fluids 87
A new chromogranin A-dependent angiogenic switch activated by thrombin 86
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours 81
TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens 80
Agents regulating vascular permeability 80
Catestatin inhibits obesity-induced macrophage infiltration and inflammation in the liver and suppresses hepatic glucose production, leading to improved insulin sensitivity 80
Spatiotemporal regulation of tumor angiogenesis by circulating chromogranin a cleavage and neuropilin-1 engagement 80
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy 77
Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study 77
Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces and iron-deficient phenotype 77
Breaching the blood–brain tumor barrier for tumor therapy 77
A Pilot Study on Continuous Infusion of 4% Albumin in Critically Ill Patients: Impact on Nosocomial Infection via a Reduction Mechanism for Oxidized Substrates 75
Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action 73
Isoaspartate-glycine-arginine: A new tumor vasculature-targeting motif 73
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) 73
Inhibition of tumor growth by intramuscular injection of cDNA encoding tumor necrosis factor alpha coupled to NGR and RGD tumor-homing peptides 73
T cells redirected to a minor histocompatibility antigen instruct intratumoral TNFα expression and empower adoptive cell therapy for solid tumors 73
Tumor necrosis factor-α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the successful treatment of patients with infliximab 73
Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to αvβ3 without Promoting Integrin Allosteric Activation 73
Chromogranin A and Its Fragments in the Critically Ill: An Expanding Domain of Interest for Better Care 70
Autocrine saturation of pro-urokinase receptors on human A431cells 70
Won't you come on in? How to favor lymphocyte infiltration in tumors 70
The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells 69
Identification of an epitope of tumor-necrosis-factor (TNF) receptor-type-1 (p55) recognized by a TNF-alpha-antagonist monoclonal-antibody 69
Oligomeric Tumor-necrosis factor alpha slowly converts into inactive forms at bioactive levels 69
Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms 69
Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer 68
Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability 68
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells 68
Mode of interaction between tumor-necrosis-factor-alpha and a monoclonal-antibody expressing a recurrent idiotype 68
Chromogranin A is preferentially cleaved into pro-angiogenic peptides in the bone marrow of multiple myeloma patients 68
Anti-idiotype monoclonal antibody directed against anti-TNF antibodies 68
Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy 67
Tumour necrosis factor: Strategies for improving the therapeutic index 67
Conversation galante: How the immune and the neuroendocrine systems talk to each other 67
Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules 67
STRUCTURAL BASIS FOR THE INTERATION OF ISODGR WITH RGD-BINDING SITE OF αvβ3 INTEGRIN 67
Mechanism of suramin-induced deoligomerization of tumor-necrosis-factor-alpha 67
IgEs targeted on tumor cells: Therapeutic activity and potential in the design of tumor vaccines 67
Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism 67
Regulation of tumor growth by circulating full-length chromogranin A 67
Nanogold Functionalized With Lipoamide-isoDGR: A Simple, Robust and Versatile Nanosystem for αvβ3-Integrin Targeting 67
The elusive role of proton pump inhibitors in COVID-19: Can plasma Chromogranin A levels hold the key? 66
Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha 66
Oxidative stress biomarkers and chromogranin A in uremic patients: Effects of dialytic treatment 66
Monoclonal antibodies against the TNF type-I receptor, process for their production and use thereofAnticorpi monoclonali anti-recettore di tipo 1 del TNF alfa, procedimento per la loro produzione e loro uso 66
Chromogranin A and the Tumor Microenvironment 66
Tumor-necrosis-factor (TNF)-alpha quantification by ELISA and bioassay - effects of TNF-alpha-soluble TNF-receptor (p55) complex dissociation during assay incubations 65
Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout 65
Liposome-Mediated Therapy of Neuroblastoma 65
Tumor necrosis factor in heart failure 65
Anti-urokinase monoclonal antibody, matrix bearing it, test method, biochemical test kits which use it. 65
Cytokine conjugates (IL-12 –peptide conjugates) 65
Ways to improve tumor uptake and penetration of drugs into solid tumors 65
Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A 64
Cromogranina A per uso come reagente in un metodo diagnostico o prognostico 64
The vasostatin-1 fragment of chromogranin A preserves a quiescent phenotype in hypoxia-driven endothelial cells and regulates tumor neovascularization 64
NF-kappa B-mediated regulation of urokinase gene expression by PMA and TNF-alpha in human A549 cells 64
Chromogranin A Regulates Tumor Self-Seeding and Dissemination 63
Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression 63
Kinetic-analysis of TNF-alpha oligomer monomer transition by surface-plasmon resonance and immunochemical method 63
Oxidation-induced structural changes of ceruloplasmin foster NGR-motifs deamidation that promote integrin binding and signaling 63
Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers 63
Critical Role of Flanking Residues in NGR-to-isoDGR Transition and CD13/Integrin Receptor Switching 62
PCR amplification of antibody variable regions using primers that anneal to constant regions 62
Totale 8.935
Salva come PNG Salva come JPEG
Categoria #
all - tutte 125.923
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 125.923
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022111 0 0 0 70 0 7 7 5 2 2 1 17
2022/20231.296 604 245 115 3 2 138 42 67 64 5 5 6
2023/2024417 5 8 62 36 26 88 24 33 0 18 37 80
2024/20253.632 461 37 54 101 80 265 744 277 649 504 226 234
2025/202610.378 698 934 771 1.635 678 199 945 746 2.734 504 181 353
2026/20272.596 318 644 593 1.041 0 0 0 0 0 0 0 0
Totale 18.516